|Mr. Kenneth M. Reali||CEO & Director||1.33M||N/A||1966|
|Mr. Gregory O. Anglum||Sr. VP & CFO||584.7k||N/A||1971|
|Ms. Alessandraa Pavesio||Sr. VP & Chief Science Officer||634.95k||N/A||1967|
|Mr. Anthony D'Adamio||Sr. VP & Gen. Counsel||618.29k||N/A||1961|
|Mr. John E. Nosenzo||Chief Commercial Officer||907.28k||N/A||1958|
|Mr. Anthony James||VP of Operations and Quality||N/A||N/A||N/A|
|Mr. Miguel O. Beltran-Delgado||Sr. VP of Operations||N/A||N/A||N/A|
|Ms. Katrina J. Church||Sr. VP & Chief Compliance Officer||N/A||N/A||1962|
|Mr. Jeff Welch||VP of Bus. Devel.||N/A||N/A||N/A|
|Mr. Leigh Ann Stradford||Sr. VP of HR||N/A||N/A||N/A|
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.